Rs 72 lakh/year rare-disease drug can be made for Rs 3,000/year, HC told

A Yale expert reveals SMA drug Risdiplam could cost Rs 3,000 annually with local production, vastly cheaper than Rs 72 lakh due to patents. A Kerala court case highlights treatment affordability issues and insufficient government financial assistance and crowdfunding efforts for patients.